FELBAMATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for felbamate and what is the scope of freedom to operate?
Felbamate
is the generic ingredient in two branded drugs marketed by Amneal Pharms, Novitium Pharma, Taro, Mylan Speciality Lp, Alvogen, Ani Pharms, and Zydus Lifesciences, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are twelve drug master file entries for felbamate. Eleven suppliers are listed for this compound.
Summary for FELBAMATE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 7 |
NDAs: | 9 |
Drug Master File Entries: | 12 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Clinical Trials: | 6 |
Patent Applications: | 6,293 |
Drug Prices: | Drug price trends for FELBAMATE |
What excipients (inactive ingredients) are in FELBAMATE? | FELBAMATE excipients list |
DailyMed Link: | FELBAMATE at DailyMed |
Recent Clinical Trials for FELBAMATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Instituto Nacional de Salud Publica, Mexico | Phase 3 |
Laboratorios Grossman, S.A. | Phase 3 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Pharmacology for FELBAMATE
Drug Class | Anti-epileptic Agent |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Anatomical Therapeutic Chemical (ATC) Classes for FELBAMATE
US Patents and Regulatory Information for FELBAMATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alvogen | FELBAMATE | felbamate | TABLET;ORAL | 204595-002 | Jan 11, 2016 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Zydus Lifesciences | FELBAMATE | felbamate | TABLET;ORAL | 208970-001 | May 30, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Zydus Lifesciences | FELBAMATE | felbamate | TABLET;ORAL | 208970-002 | May 30, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Novitium Pharma | FELBAMATE | felbamate | SUSPENSION;ORAL | 211333-001 | May 31, 2019 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Taro | FELBAMATE | felbamate | SUSPENSION;ORAL | 206314-001 | Jun 16, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FELBAMATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Speciality Lp | FELBATOL | felbamate | SUSPENSION;ORAL | 020189-003 | Jul 29, 1993 | ⤷ Subscribe | ⤷ Subscribe |
Mylan Speciality Lp | FELBATOL | felbamate | TABLET;ORAL | 020189-002 | Jul 29, 1993 | ⤷ Subscribe | ⤷ Subscribe |
Mylan Speciality Lp | FELBATOL | felbamate | TABLET;ORAL | 020189-002 | Jul 29, 1993 | ⤷ Subscribe | ⤷ Subscribe |
Mylan Speciality Lp | FELBATOL | felbamate | TABLET;ORAL | 020189-001 | Jul 29, 1993 | ⤷ Subscribe | ⤷ Subscribe |
Mylan Speciality Lp | FELBATOL | felbamate | SUSPENSION;ORAL | 020189-003 | Jul 29, 1993 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
FELBAMATE Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.